全球肺氣腫治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球肺氣腫治療市場預計將從2025年的56.5億美元成長至2034年的101.2億美元，2026年至2034年的複合年成長率（CAGR）為6.7%。該市場正經歷顯著成長，主要得益於慢性呼吸系統疾病的盛行率上升以及人們對早期診斷和治療意識的提高。肺氣腫是慢性阻塞性肺病（COPD）的主要類型，持續影響全球數百萬人口。醫療保健支出的成長和呼吸系統護理技術的進步正在推動市場擴張，並改善患者獲得治療的機會。

部分地區吸菸率上升、環境污染加劇以及人口老化是導致疾病盛行率上升和治療需求不斷成長的主要因素。製藥公司正大力投資研發，以推出更有效的治療方法並改善患者預後。診斷技術的進步和宣傳活動的加強有助於早期療育，這對市場成長產生了積極影響。

隨著創新治療方法和個人化醫療的不斷發展，前景一片光明。生物製藥、再生醫學和微創療法的進步有望為疾病管理帶來重大變革。開發中國家醫療基礎設施的擴建預計將改善患者獲得治療的機會。對呼吸系統疾病研究的持續投入將為參與企業創造巨大的成長機會。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球肺氣腫治療市場：依治療方式分類

• 市場分析、洞察與預測
• 禁止抽煙
• 支氣管擴張劑
• 類固醇
• 白三烯調節劑
• 氧氣供應
• 抗生素
• 基因治療
• 手術/移植
• 其他

第5章：全球肺氣腫治療市場：依通路分類

• 市場分析、洞察與預測
• 線上提供者
• 藥局和零售藥房
• 醫院藥房

第6章 全球肺氣腫治療市場：依最終用戶分類

• 市場分析、洞察與預測
• 診所
• 外科中心
• 其他

第7章 全球肺氣腫治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd
  • Novartis AG
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Boehringer Ingelheim GmbH
  • Mylan NV
  • Pfizer Inc
  • Orion Oyj
  • Verona Pharma PLC
  • Pulmonx Corporation
  • Bioxyne Limited
  • Intrexon Corporation
  • ICure Pharmaceuticals Inc

The global emphysema treatment market size is expected to reach USD 10.12 Billion in 2034 from USD 5.65 Billion in 2025, growing at a CAGR of 6.7 during 2026-2034.This market is witnessing significant growth due to the rising prevalence of chronic respiratory diseases and increasing awareness regarding early diagnosis and treatment. Emphysema, a major form of chronic obstructive pulmonary disease, continues to affect millions of individuals worldwide. Growing healthcare expenditures and advancements in respiratory care are supporting market expansion and improving treatment accessibility.

Increasing smoking rates in some regions, environmental pollution, and aging populations are key factors contributing to disease prevalence and treatment demand. Pharmaceutical companies are investing heavily in research and development to introduce more effective therapies and improve patient outcomes. Enhanced diagnostic technologies and greater awareness campaigns are encouraging earlier intervention, which is positively influencing market growth.

Future prospects appear promising as innovative treatment approaches and personalized medicine continue to evolve. Advancements in biologics, regenerative therapies, and minimally invasive procedures may transform disease management. Expanding healthcare infrastructure in developing economies is expected to improve patient access to treatment. Continued investment in respiratory disease research will likely create substantial growth opportunities for market participants.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Treatment

• Smoking Cessation
• Bronchodilators
• Steroids
• Leukotriene Modifiers
• Supplemental Oxygen
• Antibiotics
• Gene Therapy
• Surgery Transplant
• Other

By Distribution Channel

• Online Providers
• Drug Stores and Retail Pharmacies
• Hospital Pharmacies

By End-User

• Clinics
• Surgical Centre
• Others

COMPANIES PROFILED

• AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Novartis AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Boehringer Ingelheim GmbH, Mylan N.V., Pfizer Inc., Orion Oyj, Verona Pharma PLC, Pulmonx Corporation, Bioxyne Limited, Intrexon Corporation, iCure Pharmaceuticals Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL EMPHYSEMA TREATMENT MARKET: BY TREATMENT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Treatment
• 4.2. Smoking Cessation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Bronchodilators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Steroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Leukotriene Modifiers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Supplemental Oxygen Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Antibiotics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.8. Gene Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.9. Surgery Transplant Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.10. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL EMPHYSEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Online Providers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Drug Stores and Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL EMPHYSEMA TREATMENT MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Surgical Centre Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL EMPHYSEMA TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Treatment
  • 7.2.2 By Distribution Channel
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Treatment
  • 7.3.2 By Distribution Channel
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Treatment
  • 7.4.2 By Distribution Channel
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Treatment
  • 7.5.2 By Distribution Channel
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Treatment
  • 7.6.2 By Distribution Channel
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL EMPHYSEMA TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 AstraZeneca PLC
  • 9.2.2 Teva Pharmaceutical Industries Ltd
  • 9.2.3 Novartis AG
  • 9.2.4 GlaxoSmithKline PLC
  • 9.2.5 Hikma Pharmaceuticals PLC
  • 9.2.6 Boehringer Ingelheim GmbH
  • 9.2.7 Mylan N.V
  • 9.2.8 Pfizer Inc
  • 9.2.9 Orion Oyj
  • 9.2.10 Verona Pharma PLC
  • 9.2.11 Pulmonx Corporation
  • 9.2.12 Bioxyne Limited
  • 9.2.13 Intrexon Corporation
  • 9.2.14 ICure Pharmaceuticals Inc